Lack of Evidence for Vasoactive and Inflammatory Mediators in the Promotion of Macular Edema Associated with Epiretinal Membranes.
Lack of Evidence for Vasoactive and Inflammatory Mediators in the Promotion of Macular Edema Associated with Epiretinal Membranes.
复制标题
DOI：
10.1038/s41598-017-08997-6
复制
发表时间：
2017-09-06
影响因子：
4.6
通讯作者：
Sodhi A
中科院分区：
文献类型：
--
作者：
Applewhite BP;Babapoor-Farrokhran S;Poon D;Hassan SJ;Wellmann E;Ying HS;Semenza GL;Montaner S;Sodhi A
视网膜前膜（ERM）患者的症状发展通常与视网膜中间质液的积聚相对应[即，黄斑水肿的发展（ME）]。为了探讨药物治疗选择的潜在价值，以治疗ME患者的ERMs，我们在这里检查血管活性和炎症介质的表达在玻璃体的特发性ERMs患者。我们观察到经典血管活性因子的玻璃体浓度（例如，血管内皮生长因子）与对照组相似。使用评估102种炎性细胞因子的表达的阵列，我们同样没有观察到与对照患者相比，大多数患有ME的ERM患者的玻璃体中的细胞因子表达的显著差异。虽然阵列数据确实暗示了一组炎性细胞因子在患有重度ME的ERM患者亚组中升高（光谱域光学相干断层扫描显示中心子场厚度≥450 μm），但这些炎性细胞因子中的3种的表达，所有这些炎性细胞因子先前都与缺血性视网膜疾病中ME的促进有关，通过定量酶联免疫吸附测定没有升高。我们的结论是，治疗调节血管活性介质或炎症细胞因子可能不会影响ME的ERM患者。
The development of symptoms in patients with epiretinal membranes (ERMs) often corresponds with the accumulation of interstitial fluid in the retina [i.e., the development of macular edema, (ME)]. To explore the potential value of pharmacologic therapeutic options to treat ME in patients with ERMs, we examine here the expression of vasoactive and inflammatory mediators in the vitreous of patients with idiopathic ERMs. We observed that vitreous concentrations of classic vasoactive factors (e.g., vascular endothelial growth factor) were similar in ERM patients with ME compared to controls. Using an array assessing the expression of 102 inflammatory cytokines we similarly did not observe a marked difference in cytokine expression in the vitreous of most ERM patients with ME compared to control patients. While the array data did implicate a group of inflammatory cytokines that were elevated in a subset of ERM patients who had severe ME (central subfield thickness ≥450 μm on spectral domain optical coherence tomography), expression of 3 of these inflammatory cytokines, all previously implicated in the promotion of ME in ischemic retinal disease, were not elevated by quantitative enzyme-linked immunosorbent assay. We conclude that therapies modulating vasoactive mediators or inflammatory cytokines may not affect ME in ERM patients.
登录
查看更多内容
DOI：
10.1097/iae.0b013e3181d6df09
发表时间：
2010-10
期刊：
Retina (Philadelphia, Pa.)
影响因子：
--
作者：
Lim JI;Spee C;Hinton DR
通讯作者：
Hinton DR
影响因子：
4.1
作者：
Chen, YS;Hackett, SF;Campochiaro, PA
通讯作者：
Campochiaro, PA
影响因子：
4.6
作者：
Joshi M;Agrawal S;Christoforidis JB
通讯作者：
Christoforidis JB
DOI：
10.1073/pnas.1423765112
发表时间：
2015-06-09
影响因子：
11.1
作者：
Babapoor-Farrokhran S;Jee K;Puchner B;Hassan SJ;Xin X;Rodrigues M;Kashiwabuchi F;Ma T;Hu K;Deshpande M;Daoud Y;Solomon S;Wenick A;Lutty GA;Semenza GL;Montaner S;Sodhi A
通讯作者：
Sodhi A
影响因子：
3.7
作者：
Feng J;Zhao T;Zhang Y;Ma Y;Jiang Y
通讯作者：
Jiang Y